Beckman Coulter grows Alzheimer’s dx portfolio with CE mark for new assay
From the article
Diagnostics specialist Beckman Coulter expanded its portfolio of Alzheimer’s disease diagnostics by earning a CE mark in Europe for its Access p-Tau217 assay.
Continue reading on Fierce BiotechYou might also wanna read
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
clinicaltrials.gov·7d ago
Study Finds Variability in Performance of FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio Test for Alzheimer Disease
This cross-sectional study evaluates the clinical performance of the FDA-cleared Lumipulse plasma p-tau217/β-amyloid 1-42 ratio test for det
doi.org·5d agoNew Alzheimer’s Breakthrough Targets Disease at the Cellular Level, Shows Promise
ltcnews.com·11mo ago
https://doi.org/10.1126/science.aeb6987
doi.org·1mo ago
Blood Test Breakthrough Offers Hope for Earlier Alzheimer's Detection
ltcnews.com·1y ago
Alzheimer’s biomarkers in dental practice: Is innovation outpacing readiness?
Dentistry IQ·23d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.